IGF-1 LR3 is a synthetic analog of human Insulin-Like Growth Factor-1 (IGF-1), a peptide hormone naturally produced in the liver in response to growth hormone (GH). The LR3 form (Long Arg3) has been modified by extending the amino acid chain and substituting arginine at position 3. These modifications significantly increase its half-life (to about 20–30 hours compared to 20–30 minutes for native IGF-1) and reduce binding to IGF-binding proteins, making it more bioavailable. IGF-1 LR3 is studied in research for its potential effects on muscle growth, tissue repair, metabolism, and aging. It remains experimental and is not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Investigated for its role in stimulating muscle hypertrophy and tissue repair in preclinical models.
- Studied for effects on glucose uptake and insulin sensitivity in metabolic research.
- Explored for potential neuroprotective and regenerative properties in brain and nerve injury models.
- Examined for longevity research due to its role in cell growth, repair, and survival signaling pathways.
Proposed Uses (Research Areas)
- Muscle recovery and hypertrophy studies.
- Metabolic health research — glucose regulation and insulin sensitivity.
- Nerve repair and neuroprotection models.
- Aging and regenerative medicine research.
How It Is Dosed in Research Settings
- Injectable: Common research dosing is 20–100 mcg daily, delivered subcutaneously or intramuscularly.
- Localized vs systemic: Some protocols examine intramuscular injections near target tissues (e.g., skeletal muscle) versus systemic administration.
- Cycle length: Typically studied for 4–6 weeks, though some metabolic studies extend longer.
- Handling: Supplied as lyophilized powder; reconstituted with bacteriostatic water and stored refrigerated per research SOPs.
Important Considerations
- Regulatory status: IGF-1 LR3 is not FDA-approved; all current use is experimental and limited to research.
- Evidence base: Data is mostly from animal models and cell studies; limited human research exists outside specialized medical contexts.
- Safety: Reported risks in research include hypoglycemia, water retention, joint pain, and potential tumor growth stimulation due to its mitogenic activity. Long-term safety is unknown.
Disclaimer
This material is provided for educational purposes only and summarizes published research on IGF-1 LR3.
It is not medical advice. IGF-1 LR3 is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.